ArticleLeukemia2010
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis.
Article in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.International journal of hematology · 2012Trial
- Homozygosity of germ lineBlood neoplasia · 2026Article
- Characterization of JAK2V617F and the JAK2 46/1 germline haplotype in myeloproliferative neoplasms in a Saudi Arabian cohort: a case-based analysis.Frontiers in oncology · 2026Article
- JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms.International journal of molecular sciences · 2025Review
- Article
- Expulsion of iron-rich ferritin via CD63-mediated exosome drives ferroptosis resistance in ovarian cancer cells.Frontiers in cell and developmental biology · 2025Article
- ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis.Journal of experimental & clinical cancer research : CR · 2023Article
- Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma.Frontiers in cell and developmental biology · 2023Article
- TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.International journal of hematology · 2019Article
- The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?International journal of molecular sciences · 2018Review
- JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.Leukemia · 2013Article
- Inherited predisposition to myeloproliferative neoplasms.Therapeutic advances in hematology · 2013Article
- The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.Medical oncology (Northwood, London, England) · 2012Article
- Convergent mechanisms of somatic mutations in polycythemia vera.Discovery medicine · 2011Article
- Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.Blood cancer journal · 2011Article
- JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.Leukemia · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20520633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.